Perrigo Company PLC (PRGO): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Perrigo Company ( PRGO) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 2.0%. By the end of trading, Perrigo Company rose $2.75 (1.7%) to $161.70 on average volume. Throughout the day, 1,277,952 shares of Perrigo Company exchanged hands as compared to its average daily volume of 1,328,700 shares. The stock ranged in a price between $158.00-$161.76 after having opened the day at $158.83 as compared to the previous trading day's close of $158.95. Other companies within the Health Care sector that increased today were: Rexahn Pharmaceuticals ( RNN), up 70.0%, Intercept Pharmaceuticals ( ICPT), up 61.6%, Conatus Pharmaceuticals ( CNAT), up 45.4% and Endocyte ( ECYT), up 28.6%.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Perrigo Company has a market cap of $14.9 billion and is part of the drugs industry. The company has a P/E ratio of 32.8, above the S&P 500 P/E ratio of 17.7. Shares are up 3.5% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Perrigo Company a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Chelsea Therapeutics International ( CHTP), down 29.2%, Mast Therapeutics ( MSTX), down 27.7%, MannKind Corporation ( MNKD), down 16.4% and Aegerion Pharmaceuticals ( AEGR), down 10.8% , were all laggards within the health care sector with DaVita HealthCare Partners ( DVA) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

McDonald's Takes Bite Out of Dow, but Nasdaq and S&P 500 at Records

Perrigo Stock Jumps as Starboard's Smith Says Generic Drugs a Strong Business

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

These Stocks Have Changed Direction

Stocks Tank as Trump, North Korea Exchange Barbs